Búsqueda | Biblioteca Virtual en Salud

1.

A randomized phase 1b trial of the active site polymerase inhibitor nucleotide ATI-2173 in patients with chronic hepatitis B virus infection.

Squires, Katherine E; Ogilvie, Lauren; Jucov, Alina; Anastasiy, Igor; Ghicavii, Nelli; Huguet, Jade; Melara, Rebeca; Constantineau, Martin; De La Rosa, Abel; Mayers, Douglas L.

J Viral Hepat ; 30(1): 19-28, 2023 01.

Artículo en Inglés | MEDLINE | ID: mdl-36201354

2.

ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens.

Squires, Katherine E; Mayers, Douglas L; Bluemling, Gregory R; Kolykhalov, Alexander A; Guthrie, David B; Reddy, Prabhakar; Mitchell, Debbie G; Saindane, Manohar T; Sticher, Zachary M; Edpuganti, Vindhya; De La Rosa, Abel.

Antimicrob Agents Chemother ; 64(9)2020 08 20.

Artículo en Inglés | MEDLINE | ID: mdl-32540975

3.

Population pharmacokinetics of telbivudine and determination of dose adjustment for patients with renal impairment.

Zhou, Xiao-Jian; Ke, June; Sallas, William M; Farrell, Colm; Mayers, Douglas L; Pentikis, Helen S.

J Clin Pharmacol ; 49(6): 725-34, 2009 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-19395586

4.

Ebola virus disease: an update on post-exposure prophylaxis.

Fischer, William A; Vetter, Pauline; Bausch, Daniel G; Burgess, Timothy; Davey, Richard T; Fowler, Robert; Hayden, Frederick G; Jahrling, Peter B; Kalil, Andre C; Mayers, Douglas L; Mehta, Aneesh K; Uyeki, Timothy M; Jacobs, Michael.

Lancet Infect Dis ; 18(6): e183-e192, 2018 06.

Artículo en Inglés | MEDLINE | ID: mdl-29153266

5.

Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.

Lawrence, Jody; Mayers, Douglas L; Hullsiek, Katherine Huppler; Collins, Gary; Abrams, Donald I; Reisler, Ronald B; Crane, Lawrence R; Schmetter, Barry S; Dionne, Thomas J; Saldanha, Jennifer M; Jones, Michael C; Baxter, John D.

N Engl J Med ; 349(9): 837-46, 2003 Aug 28.

Artículo en Inglés | MEDLINE | ID: mdl-12944569

6.

Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy.

Baxter, John D; Merigan, Thomas C; Wentworth, Deborah N; Neaton, James D; Hoover, Marie L; Hoetelmans, Richard M W; Piscitelli, Stephen C; Verbiest, Werner H A; Mayers, Douglas L.

AIDS ; 16(8): 1131-8, 2002 May 24.

Artículo en Inglés | MEDLINE | ID: mdl-12004271

7.

Current status of chemically synthesized inhibitors of Ebola virus.

Cardile, Anthony P; Mayers, Douglas L; Bavari, Sina.

Recent Pat Antiinfect Drug Discov ; 9(2): 97-103, 2014.

Artículo en Inglés | MEDLINE | ID: mdl-25808170

8.

Seeking ethical designs for HIV clinical trials in treatment-experienced patients: an industry perspective.

Mayers, Douglas L; Chung, Jain; Kohlbrenner, Veronika M; Hall, David B; DeMasi, Ralph A; Neubacher, Dietmar; Buss, Neil E; Salgo, Miklos P.

AIDS Res Hum Retroviruses ; 22(11): 1110-2, 2006 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-17147497

9.

Optimization of allele-specific PCR using patient-specific HIV consensus sequences for primer design.

Boltz, Valerie F; Maldarelli, Frank; Martinson, Neil; Morris, Lynn; McIntyre, James A; Gray, Glenda; Hopley, Mark J; Kimura, Toshio; Mayers, Douglas L; Robinson, Patrick; Mellors, John W; Coffin, John M; Palmer, Sarah E.

J Virol Methods ; 164(1-2): 122-6, 2010 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-19948190

10.

Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir.

Baxter, John D; Schapiro, Jonathan M; Boucher, Charles A B; Kohlbrenner, Veronika M; Hall, David B; Scherer, Joseph R; Mayers, Douglas L.

J Virol ; 80(21): 10794-801, 2006 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-16928764

11.

Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study.

Lawrence, Jody; Hullsiek, Katherine Huppler; Thackeray, Lisa M; Abrams, Donald I; Crane, Lawrence R; Mayers, Douglas L; Jones, Michael C; Saldanha, Jennifer M; Schmetter, Barry S; Baxter, John D.

J Acquir Immune Defic Syndr ; 43(2): 169-78, 2006 Oct 01.

Artículo en Inglés | MEDLINE | ID: mdl-16951642

12.

Antimicrobial Drug Resistance : Clinical and Epidemiological Aspects

Mayers, Douglas L.

Totowa, NJ; Humana Press; 2009. 1370 p.

Monografía en Inglés | Bibliografia | ID: bib-343276

13.

Antimicrobial Drug Resistance : Mechanisms of Drug Resistance

Mayers, Douglas L.

Totowa, NJ; Humana Press; 2009. 678 p.

Monografía en Inglés | Bibliografia | ID: bib-342991

14.

A 14-day dose-response study of the efficacy, safety, and pharmacokinetics of the nonpeptidic protease inhibitor tipranavir in treatment-naive HIV-1-infected patients.

McCallister, Scott; Valdez, Hernan; Curry, Kevin; MacGregor, Thomas; Borin, Marie; Freimuth, William; Wang, Yenyung; Mayers, Douglas L.

J Acquir Immune Defic Syndr ; 35(4): 376-82, 2004 Apr 01.

Artículo en Inglés | MEDLINE | ID: mdl-15097154

15.

A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients.

Stern, Jerry O; Robinson, Patrick A; Love, James; Lanes, Stephan; Imperiale, Michael S; Mayers, Douglas L.

J Acquir Immune Defic Syndr ; 34 Suppl 1: S21-33, 2003 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-14562855

16.

The lack of therapeutic benefit of adding hydroxyurea to highly active antiretroviral therapy (HAART).

Gonzalez, Omar Y; Jovanovich, John F; Mayers, Douglas L; Musher, Daniel M.

J Acquir Immune Defic Syndr ; 30(3): 363-4, 2002 Jul 01.

Artículo en Inglés | MEDLINE | ID: mdl-12131575

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar: